Evidence map›Paper›PMID 34511566›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Neurological Manifestations and Long-term Sequelae in Hospitalized Patients with COVID-19.

Hiroyuki Ishiyama, Junko Ishii, Hajime Yoshimura, Marie Tsunogae, Satoru Fujiwara, Satomi Hiya, Ryoma Inui, Yuma Shiomi, Shinsaku Nakazawa, Masamune Kimura and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Hiroyuki IshiyamaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Junko IshiiDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Hajime YoshimuraDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Marie TsunogaeDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Satoru FujiwaraDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Satomi HiyaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Ryoma InuiDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Yuma ShiomiDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Shinsaku NakazawaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Masamune KimuraDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Takehito KurodaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Yasutaka MurakamiDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Kota MaekawaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Nobuyuki OharaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Nobuo KoharaDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Michi KawamotoDepartment of Neurology, Kobe City Medical Center General Hospital, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Various neurological manifestations have been increasingly reported in coronavirus disease 2019 (COVID-19). We determined the neurological features and long-term sequelae in hospitalized COVID-19 patients. Methods We retrospectively studied 95 consecutive hospitalized patients with COVID-19 between March 1 and May 13, 2020. Acute neurological presentations (within two weeks of the symptom onset of COVID-19) were compared between 60 non-severe and 35 severely infected patients who required high-flow oxygen. In the 12 ventilated patients (the most severe group), we evaluated neurological complications during admission, subacute neurological presentations, and neurological sequelae (51 and 137 days from the onset [median], respectively). Results Of the 95 patients (mean age 53 years old; 40% women), 63% had acute neurological presentations, with an increased prevalence in cases of severe infections (83% vs. 52%, p<0.001). Impaired consciousness and limb weakness were more frequent in severe patients than in non-severe ones (0% vs. 49%; p<0.001, and 0% vs. 54%; p<0.001, respectively). In the most severe group (mean age 72 years old; 42% women), 83% of patients had neurological complications [cerebrovascular disease (17%), encephalopathy (82%), and neuropathy (55%)], and 92% had subacute neurological presentations [impaired consciousness (17%), higher brain dysfunction (82%), limb weakness (75%), and tremor (58%)]. Neurological sequelae were found in 83% of cases, including higher brain dysfunction (73%), limb weakness (50%), and tremor (58%). Conclusions Neurological manifestations are common in COVID-19, with the possibility of long-lasting sequelae.

Indexed as

COVID-19Nervous System DiseasesAgedFemaleHospitalizationHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2COVID-19infectious diseasesintensive and critical careneurology

Identifiers

PMID34511566
PMCPMC8666216
OpenAlexW3200397951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.